A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Norman Wolmark, MD
NSABP Foundation
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
51 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- St. Joseph Hospital of Orange
Orange, California, United States
- St. Joseph Heritage Healthcare
Santa Rosa, California, United States
- Kaiser Permanente Medical Center - Vallejo
Vallejo, California, United States
- Colorado Cancer Research Program
Denver, Colorado, United States
- Yale University
New Haven, Connecticut, United States
- University of Florida
Gainesville, Florida, United States
- Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, United States
- Memorial Health University Medical Center
Savannah, Georgia, United States
- Cancer Care Specialists of Illinois - Decatur Memorial Hospital
Decatur, Illinois, United States
- Edward Hospital Cancer Center
Naperville, Illinois, United States
- Carle Cancer Center
Urbana, Illinois, United States
- Northern Indiana Cancer Research Consortium
South Bend, Indiana, United States
- Oncology Associates at Mercy Medical Center
Cedar Rapids, Iowa, United States
- Genesis Medical Center - West Campus
Davenport, Iowa, United States
- University of Iowa
Iowa City, Iowa, United States
- Covenant Cancer Treatment Center
Waterloo, Iowa, United States
- Norton Cancer Institute, Norton Healthcare Pavilion
Louisville, Kentucky, United States
- Tulane University Health Sciences Center
New Orleans, Louisiana, United States
- New England Cancer Specialists
Scarborough, Maine, United States
- Berkshire Medical Center Cancer and Infusion Center
Pittsfield, Massachusetts, United States
- Breslin Cancer Center
Lansing, Michigan, United States
- Metro Minnesota Community Oncology Research Consortium
Saint Louis Park, Minnesota, United States
- Missouri Valley Cancer Consortium
Omaha, Nebraska, United States
- Nevada Cancer Research Foundation, Inc.
Las Vegas, Nevada, United States
- Md Anderson Cancer Center at Cooper
Camden, New Jersey, United States
- Monmouth Medical Center
Long Branch, New Jersey, United States
- Newark Beth Israel Medical Center
Newark, New Jersey, United States
- Community Medical Center
Toms River, New Jersey, United States
- Waverly Hematology Oncology
Cary, North Carolina, United States
- Caromont Regional Medical Center
Gastonia, North Carolina, United States
- Margaret R. Pardee Memorial Hospital
Hendersonville, North Carolina, United States
- First Health of the Carolinas Cancer Center
Pinehurst, North Carolina, United States
- Wake Forest Baptist Health
Winston-Salem, North Carolina, United States
- James Cancer Hospital and Solove Research Institute at the Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
- Toledo Clinic Cancer Center
Toledo, Ohio, United States
- Abington Hospital -Jefferson South
Abington, Pennsylvania, United States
- Penn State Cancer Institute at Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States
- Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
- Allegheny General Hospital
Pittsburgh, Pennsylvania, United States
- Upmc Cancer Centers
Pittsburgh, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2016
- Primary completion
- 31 Oct 2019
- Completion
- 31 Oct 2019
- Last update posted
- 14 Apr 2022
- Registered enrollment
- 34
- Registry id
- NCT02664077
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.